42 related articles for article (PubMed ID: 19502452)
1. Risk Stratification of Pancreatic Neuroendocrine Neoplasms Based on Clinical, Pathological, and Molecular Characteristics.
Choi JH; Paik WH
J Clin Med; 2022 Dec; 11(24):. PubMed ID: 36556070
[TBL] [Abstract][Full Text] [Related]
2. Characterization of circulating immune cells and correlation with Tie2/Angiopoietins level in well differentiated neuroendocrine gastroenteropancreatic tumors: a cross-sectional analysis.
Sesti F; Puliani G; Feola T; Campolo F; Sciarra F; Hasenmajer V; Lenzi A; Faggiano A; Isidori AM; Venneri MA; Giannetta E
Endocrine; 2023 Apr; 80(1):221-230. PubMed ID: 36509928
[TBL] [Abstract][Full Text] [Related]
3. Angioside: The role of Angiogenesis and Hypoxia in Lung Neuroendocrine Tumours According to Primary Tumour Location in Left or Right Parenchyma.
La Salvia A; Carletti R; Verrico M; Feola T; Puliani G; Bassi M; Sesti F; Pernazza A; Mazzilli R; Lamberti G; Siciliani A; Mancini M; Manai C; Venuta F; Ibrahim M; Tomao S; D'Amati G; Di Gioia C; Giannetta E; Cappuzzo F; Faggiano A
J Clin Med; 2022 Oct; 11(19):. PubMed ID: 36233825
[TBL] [Abstract][Full Text] [Related]
4. Immunoregulation and clinical significance of neutrophils/NETs-ANGPT2 in tumor microenvironment of gastric cancer.
Yang S; Zou X; Li J; Yang H; Zhang A; Zhu Y; Zhu L; Zhang L
Front Immunol; 2022; 13():1010434. PubMed ID: 36172371
[TBL] [Abstract][Full Text] [Related]
5. Circulating Angiogenic Markers in Gastroenteropancreatic Neuroendocrine Neoplasms: A Systematic Review.
Sandra I; Cazacu IM; Croitoru VM; Mihaila M; Herlea V; Diculescu MM; Dima SO; Croitoru AE
Curr Issues Mol Biol; 2022 Sep; 44(9):4001-4014. PubMed ID: 36135186
[TBL] [Abstract][Full Text] [Related]
6. Angiogenic and angiostatic factors present in the saliva of malaria patients.
Lekpor CE; Botchway F; Kusi KA; Adjei AA; Wilson MD; Stiles JK; Wilson NO
Malar J; 2022 Jul; 21(1):220. PubMed ID: 35836234
[TBL] [Abstract][Full Text] [Related]
7. An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms.
Fang JM; Li J; Shi J
World J Gastroenterol; 2022 Mar; 28(10):1009-1023. PubMed ID: 35431496
[TBL] [Abstract][Full Text] [Related]
8. Angiogenic factors as prognostic markers in neuroendocrine neoplasms.
Puliani G; Sesti F; Anastasi E; Verrico M; Tarsitano MG; Feola T; Campolo F; Di Gioia CRT; Venneri MA; Angeloni A; Appetecchia M; Lenzi A; Isidori AM; Faggiano A; Giannetta E;
Endocrine; 2022 Apr; 76(1):208-217. PubMed ID: 35088292
[TBL] [Abstract][Full Text] [Related]
9. Significance of Serum Angiopoietin-2 in Patients with Hemorrhage in Adult-Onset Moyamoya Disease.
Yu J; Huang K; Pan J; Shen J; Zhan R
Biomed Res Int; 2020; 2020():8209313. PubMed ID: 32802878
[TBL] [Abstract][Full Text] [Related]
10. The use of biomarkers in neuroendocrine tumours.
Khan MS; Caplin ME
Frontline Gastroenterol; 2013 Jul; 4(3):175-181. PubMed ID: 28839724
[TBL] [Abstract][Full Text] [Related]
11. Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma.
Gayed BA; Gillen J; Christie A; Peña-Llopis S; Xie XJ; Yan J; Karam JA; Raj G; Sagalowsky AI; Lotan Y; Margulis V; Brugarolas J
BMC Urol; 2015 Apr; 15():24. PubMed ID: 25885592
[TBL] [Abstract][Full Text] [Related]
12. Expression of angiopoietin-TIE system components in angiosarcoma.
Buehler D; Rush P; Hasenstein JR; Rice SR; Hafez GR; Longley BJ; Kozak KR
Mod Pathol; 2013 Aug; 26(8):1032-40. PubMed ID: 23558570
[TBL] [Abstract][Full Text] [Related]
13. Elevated peripheral blood plasma concentrations of tie-2 and angiopoietin 2 in patients with neuroendocrine tumors.
Melen-Mucha G; Niedziela A; Mucha S; Motylewska E; Lawnicka H; Komorowski J; Stepien H
Int J Mol Sci; 2012; 13(2):1444-1460. PubMed ID: 22408401
[TBL] [Abstract][Full Text] [Related]
14. Targeting the ANGPT-TIE2 pathway in malignancy.
Huang H; Bhat A; Woodnutt G; Lappe R
Nat Rev Cancer; 2010 Aug; 10(8):575-85. PubMed ID: 20651738
[TBL] [Abstract][Full Text] [Related]
15. Circulating angiopoietin-2 is elevated in patients with neuroendocrine tumours and correlates with disease burden and prognosis.
Srirajaskanthan R; Dancey G; Hackshaw A; Luong T; Caplin ME; Meyer T
Endocr Relat Cancer; 2009 Sep; 16(3):967-76. PubMed ID: 19502452
[TBL] [Abstract][Full Text] [Related]
16. Angiopoietin-2 promotes disease progression of neuroendocrine tumors.
Detjen KM; Rieke S; Deters A; Schulz P; Rexin A; Vollmer S; Hauff P; Wiedenmann B; Pavel M; Scholz A
Clin Cancer Res; 2010 Jan; 16(2):420-9. PubMed ID: 20068079
[TBL] [Abstract][Full Text] [Related]
17. The association of the angiopoietin/Tie-2 system with the development of metastasis and leukocyte migration in neuroendocrine tumors.
Figueroa-Vega N; Díaz A; Adrados M; Alvarez-Escolá C; Paniagua A; Aragonés J; Martín-Pérez E; Leskela S; Moreno-Otero R; González-Amaro R; Marazuela M
Endocr Relat Cancer; 2010 Dec; 17(4):897-908. PubMed ID: 20696814
[TBL] [Abstract][Full Text] [Related]
18. Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina.
Belli SH; Oneto A; Aranda C; O'Connor JM; Domenichini E; Roca E; Méndez G; Bestani MC; Parma P; Giacomi N; Marmissolle F
Acta Gastroenterol Latinoam; 2009 Sep; 39(3):184-9. PubMed ID: 19845257
[TBL] [Abstract][Full Text] [Related]
19. Circulating biomarkers in neuroendocrine tumors of the enteropancreatic tract: application to diagnosis, monitoring disease, and as prognostic indicators.
Ardill JE; O'Dorisio TM
Endocrinol Metab Clin North Am; 2010 Dec; 39(4):777-90. PubMed ID: 21095544
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
